Advanced Filters
noise

Isleworth, United Kingdom Clinical Trials

A listing of Isleworth, United Kingdom clinical trials actively recruiting patients volunteers.

Found 740 clinical trials
R R&I Administrator

Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes

Over 7,000 people in the UK are living with Myelodysplastic Syndromes (MDS). Approximately 1,600 of these individuals (23%) die each year from their disease. MDS affects the production of blood cells by the bone marrow, causing chronic fatigue, bleeding, and recurrent infections. Many patients die because their disease transforms into …

18 years of age All Phase 2

CAR T Cells to Target GD2 for DMG

The CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of generating the ATIMP, the safety and tolerability of the …

- 16 years of age All Phase 1
C Christen Lauder

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

The purpose of this dose escalation study is to evaluate the safety profile of escalating doses and dose schedules of NXP900.

18 years of age All Phase 1
A Alison Ray

A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer

This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and …

18 years of age All Phase 2
I Ian Jenkins

Beyond TME Origins

All patients with recurrent colorectal cancer in the pelvis are eligible. The original primary tumour staging scans and resected surgical specimen needs to be available. Patients' recurrence will be staged using our proposed MRI classification. We will be assessing the original primary staging scans and histopathology to learn about risk …

16 years of age All Phase N/A
M Matthew Krebs, Prof

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

This clinical trial is looking at a drug called atezolizumab. Atezolizumab is approved as standard of care treatment for adult patients with urothelial cancer, non-small cell lung cancer, extensive-stage breast small cell lung cancer, hepatocellular carcinoma and triple negative cancer. This means it has gone through clinical trials and been …

years of age All Phase 2/3
S Stephen Liu

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies

18 years of age All Phase 1/2
N Nicola Gibbons

Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers

Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. Patient are randomised to the control arm which the standard care of preoperative CT imaging and subsequent discussion by the Multidisciplinary …

16 years of age All Phase N/A
R Riti Desai, M.Sc, M.Phil

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces. These cells can be damaged by a disease called wet age-related macular degeneration (AMD), where new abnormal blood vessels grow through the …

50 - 120 years of age All Phase 3
R Rohini Sharma, MD

Lutathera and ASTX727 in Neuroendocrine Tumours

Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the …

18 - 99 years of age All Phase 1

Simplify language using AI